×
About 16,350 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  6,012 results

Pridopidine modifies disease phenotype in a SOD1 mouse model of Amyotrophic Lateral Scl...
https://doi.org/10.1111/ejn.15608
The European Journal of Neuroscience; Estévez-Silva HM, Mediavilla T et. al.

Jan 27th, 2022 - Amyotrophic lateral sclerosis (ALS) is a lethal and incurable neurodegenerative disease due to the loss of upper and lower motor neurons, which leads to muscle weakness, atrophy, and paralysis. Sigma-1 receptor (σ-1R) is a ligand-operated protein ...

Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis.
https://doi.org/10.1186/s13024-022-00515-1 10.1016/S1474-4422(14)70129-2 10.1016/S1474-4422(07)70270-3 10.3988/jcn.2015.11.2.164 10.1136/bmjopen-2019-029449 10.1080/21678421.2019.1632346 10.1016/j.neuron.2011.09.010 10.1016/j.neuron.2011.09.011 10.1038/nn.3584 10.1056/NEJM199403033300901 10.1038/ncomms12408 10.1080/14728214.2020.1769067 10.1016/S1474-4422(16)30199-5 10.1016/S1474-4422(08)70293-X 10.1212/WNL.0000000000003741 10.1007/s00415-017-8730-6 10.1136/jnnp-2018-318704 10.3389/fneur.2020.00279 10.1016/S1474-4422(11)70015-1 10.1016/S1474-4422(18)30394-6 10.3109/21678421.2014.903974 10.1186/s40364-019-0154-2 10.1002/mus.27046 10.3389/fmolb.2020.574133 10.1016/j.brainres.2019.146625 10.1038/s41598-020-72247-5 10.1038/s41598-020-62756-8 10.1111/j.1600-0404.2008.01112.x 10.3389/fneur.2020.552295 10.1080/21678421.2020.1779303 10.1089/brain.2020.0741 10.1002/acn3.51078 10.1016/j.jns.2019.01.026 10.1016/j.jns.2018.08.033 10.3389/fneur.2017.00546 10.1186/s13195-017-0316-0 10.1111/ane.12851 10.1038/s41598-017-09097-1 10.1017/cjn.2016.284 10.1186/1742-2094-11-94 10.1016/j.jneuroim.2012.05.001 10.1186/1742-2094-7-76 10.1007/s12640-009-9129-7 10.1111/j.1468-1331.2009.02560.x 10.1007/s11064-007-9564-x 10.1080/17482960701419232 10.1002/mus.20376 10.1016/j.jneuroim.2003.08.042 10.1016/j.celrep.2012.02.009 10.1098/rsob.200116 10.1080/21678421.2018.1433689 10.1038/s41586-020-2625-x 10.1186/s12974-018-1135-3 10.1038/s41598-017-08233-1 10.1371/journal.pone.0182002 10.1001/jamaneurol.2017.0357 10.1096/fj.201600259RR 10.1016/j.clim.2013.04.010 10.1016/j.jneuroim.2004.10.009 10.1111/ane.13401 10.3389/fnins.2020.602235 10.1002/mus.24979 10.3389/fneur.2021.629332 10.1111/ene.14409 10.1001/jamaneurol.2016.6179 10.1038/s41598-019-39739-5 10.3109/21678421.2014.951940 10.1002/emmm.201201544 10.1093/brain/118.3.707 10.1212/WNL.0000000000006855 10.1016/S1474-4422(18)30089-9 10.1080/21678421.2019.1587634 10.1073/pnas.2001429117 10.1002/ana.25276 10.1212/WNL.0000000000007242 10.1038/s41582-020-00434-z 10.3390/cells9081822 10.1002/mus.27339 10.1016/j.mayocp.2018.09.009 10.1111/j.1398-9995.2006.01058.x 10.1586/eci.09.31 10.1056/NEJMoa2003715 10.1016/j.bjae.2019.11.002 10.1200/JCO.2005.02.4364 10.3390/brainsci10020119 10.1080/01616412.2021.1893564 10.1212/NXI.0000000000000100 10.1038/s41467-019-14118-w 10.1002/mus.26106 10.3389/fnmol.2018.00288 10.1016/j.neurobiolaging.2017.03.027 10.1016/S1474-4422(16)30246-0 10.1007/s12035-019-1627-x 10.1186/s12865-016-0144-1 10.1016/j.pneurobio.2011.04.012 10.1038/469156a
Molecular Neurodegeneration; Staats KA, Borchelt DR et. al.

Jan 26th, 2022 - Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary e...

The amyloid state of proteins: A boon or bane?
https://doi.org/10.1016/j.ijbiomac.2022.01.115
International Journal of Biological Macromolecules; Hassan MN, Nabi F et. al.

Jan 26th, 2022 - Proteins and their aggregation is significant field of research due to their association with various conformational maladies including well-known neurodegenerative diseases like Alzheimer's (AD), Parkinson's (PD), and Huntington's (HD) diseases. ...

Plateaus and reversals evaluated by different methods in patients with limb-onset amyot...
https://doi.org/10.1016/j.jocn.2022.01.016
Journal of Clinical Neuroscience : Official Journal of Th... Hu N, Shen D et. al.

Jan 26th, 2022 - To determine the difference in frequency of amyotrophic lateral sclerosis (ALS) reversals and plateaus in limb-onset patients evaluated with different methods. One hundred and eighteen patients with limb-onset ALS were prospectively recruited. ALS...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  179 results

Online Self-Compassion Course for pALS (Compassion pALS)
https://clinicaltrials.gov/ct2/show/NCT05202743

Jan 21st, 2022 - Optimizing quality of life for people with ALS is a primary goal of ALS multidisciplinary care, Therefore, it is especially important to conduct research into interventions to address the psychological needs and well-being of people with ALS. Rece...

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT04944784

Jan 13th, 2022 - COURAGE-ALS is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS. The screening and qualification period for the trial will be no more than 14 days in duration. Approximately 555 eligib...

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
https://clinicaltrials.gov/ct2/show/NCT05189106

Jan 12th, 2022 - Overview of Clinical Trial: Many age-associated neurodegenerative diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), are associated with increased inflammatory signaling in the central nervous system. While there...

Use of 1 Minute Sit to Stand Test for Physical Capacity and Effort Related Desaturation in Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05151211

Jan 11th, 2022 - The aim of this study is to investigate the usability of the 1 Minute Sit to Stand Test (1 MSTS) in evaluating physical capacity and effort-related desaturation in individuals with Amyotrophic Lateral Sclerosis (ALS). In this context, patients dia...

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS
https://clinicaltrials.gov/ct2/show/NCT05003921

Jan 5th, 2022 - Amyotrophic lateral sclerosis is a devastating disease. There is evidence that mesenchymal stem cell treatment is safe and can improve the prognosis of afflicted patients. Patients with ALS will receive three intrathecal injections of cultured all...

see more →

News  319 results

Long-Term Adjunctive Edaravone for ALS: Latest Findings
https://www.medscape.com/viewarticle/966717

Jan 17th, 2022 - Dr Simon Witzel Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict those from the drug trial the US ...

Long NFL Careers Significantly Boost ALS Risk, but What's at Play?
https://www.medscape.com/viewarticle/964853

Dec 15th, 2021 - National Football League players are nearly four times more likely to develop amyotrophic lateral sclerosis (ALS) than men in the general population, with long-term players at greatest risk, a new study shows. The findings are the latest to show i...

Lipid Levels Tied to ALS Risk
https://www.medscape.com/viewarticle/958730

Sep 14th, 2021 - Elevated levels of high-density lipoprotein (HDL) and apolipoprotein A1 (apoA1) are associated with a reduced risk for amyotrophic lateral sclerosis (ALS), new research shows. The study also linked a higher ratio of total cholesterol to HDL with a...

Eyes Spy Brain Amyloid; Irisin-Cognition Link; A Look at Anti-IgLON5 Disease
https://www.medpagetoday.com/neurology/generalneurology/94184

Aug 24th, 2021 - Retinal fundus imaging to detect amyloid deposits in eyes correlated with brain amyloid PET, a small pilot study showed. (Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring) Mentally stimulating jobs may lower dementia risk, three ...

AstraZeneca's Antibody Therapy Prevents COVID-19, Study Shows
https://www.medscape.com/viewarticle/956953

Aug 23rd, 2021 - (Reuters) - AstraZeneca's new antibody therapy reduced the risk of people developing COVID-19 symptoms by 77% in a late-stage trial, putting the drugmaker on track to offer protection to those who respond poorly to vaccines. The company said on Fr...

see more →

Patient Education  10 results see all →